Germany's inflation rate ticked higher at the start of 2025, driven by rising food costs and persistent service price increases, even as energy prices provided some relief.
As Southeast Asian foreign ministers gather in Cebu, ASEAN reaffirms its commitment to a stalled five-point peace consensus for Myanmar. While acknowledging the plan's failure to halt the civil war, Thai diplomats suggest recent elections—though widely criticized—could offer a new avenue for dialogue and humanitarian access.
Intel's contract chipmaking division is reportedly in advanced discussions with tech giants Nvidia and Apple to manufacture key components starting in 2028, a potential game-changer for the semiconductor industry's supply chain.
Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.
Dollar Tree shares have experienced notable turbulence, with a sharp weekly drop contrasting a strong yearly performance. This analysis delves into the conflicting valuation signals and the macroeconomic pressures shaping the discount retailer's investment narrative.
Vodafone Group's shares have soared over 62% in the past year, dramatically outperforming the broader market. As the stock consolidates near £1.06, investors are grappling with a critical question: does the rally still have legs, or has the value opportunity evaporated? A deep dive into cash flow and valuation metrics suggests the story may be more complex than the headline numbers imply.
ARK Invest's founder capitalized on recent market weakness to increase holdings in three of her flagship disruptive innovation picks, signaling continued conviction despite sector volatility.
In its Q4 2025 letter, Greenlight Capital revealed a new position in dental distributor Henry Schein (HSIC), arguing the stock presents an opportunity for operational improvement and shareholder returns, despite recent underperformance.
In a landmark deal, AstraZeneca has licensed a suite of next-generation weight-loss drugs from China's CSPC, aiming to challenge the dominance of Lilly and Novo Nordisk with longer-acting monthly injectables.
Amid market volatility, these three companies offering yields above 4% present a compelling case for income-focused investors, backed by strategic pivots and resilient business models.
Lam Research capitalizes on soaring demand for AI chipmaking equipment, reporting record quarterly and annual revenue. While the company is aggressively expanding capacity to address supply chain bottlenecks, some analysts question if its valuation already reflects the AI-driven growth.
The long-term strategic partnership will leverage IQVIA's data-as-a-service platform to unify and streamline commercial data across 59 countries, aiming to accelerate product launches and enhance decision-making for the pharmaceutical giant.
Freeman Gold Corp. (CVE:FMAN) surged 13% last week, with retail investors—who control 56% of the company—benefiting most alongside insiders. The significant retail ownership underscores their influence on corporate decisions in this junior mining firm.
Israeli authorities announce the reopening of the Rafah crossing this Sunday, ending a nearly two-year blockade of Gaza's sole passage to Egypt.
Israel announces the Rafah border crossing will reopen this Sunday for limited travel between Gaza and Egypt, marking a significant shift in access for the enclave's 2 million residents after an eight-month Israeli control of the vital gateway.
Israel announces the reopening of the Rafah border crossing with Egypt this Sunday, permitting limited two-way movement for Palestinians after nearly 24 months of tight restrictions. The move is seen as a key development in international ceasefire efforts.
Baldwin Insurance Group (BWIN) shares have faced significant pressure, dropping over 13% in a week. With a one-year loss of 45%, investors are questioning if the sell-off presents a buying opportunity or signals deeper issues. Our analysis digs into the valuation debate and key risks.
Klarna Group faces a dual challenge: surging commercial demand for its 'buy now, pay later' services and intensifying legal scrutiny over alleged IPO disclosure failures regarding credit risk. The stock's sharp decline shifts investor focus to upcoming quarterly results and credit quality metrics.
Ziff Davis (ZD) shares show signs of a recent rebound, posting double-digit gains over the last quarter. Yet, a steep annual decline leaves investors questioning if the digital media firm is undervalued or facing structural headwinds. We break down the valuation debate and key risks.
The SAS subsidiary's new enhancement leverages vastly expanded consumer rate shopping data, offering hoteliers granular visibility across room types and distribution channels to refine pricing strategies.
